Predictive Response to Immunotherapy Score: A Useful Tool for Identifying Eligible Patients for Allergen Immunotherapy
Ilaria Mormile,
Francescopaolo Granata,
Aikaterini Detoraki,
Daniela Pacella,
Francesca Della Casa,
Felicia De Rosa,
Antonio Romano,
Amato de Paulis,
Francesca Wanda Rossi
Affiliations
Ilaria Mormile
Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy
Francescopaolo Granata
Department of Internal Medicine, Clinical Immunology, Clinical Pathology, and Infectious Diseases, Azienda Ospedaliera Universitaria Federico II, 80131 Naples, Italy
Aikaterini Detoraki
Department of Internal Medicine, Clinical Immunology, Clinical Pathology, and Infectious Diseases, Azienda Ospedaliera Universitaria Federico II, 80131 Naples, Italy
Daniela Pacella
Department of Public Health, University of Naples Federico II, 80131 Naples, Italy
Francesca Della Casa
Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy
Felicia De Rosa
Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy
Antonio Romano
Department of Neurosciences, Reproductive and Odontostomatological Sciences, Maxillofacial Surgery Unit, University of Naples Federico II, 80131 Naples, Italy
Amato de Paulis
Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy
Francesca Wanda Rossi
Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy
A specific predictive tool of allergen immunotherapy (AIT) outcome has not been identified yet. This study aims to evaluate the efficacy of a disease score referred to as Predictive Response to Immunotherapy Score (PRIS) to predict the response to AIT and identify eligible patients. A total of 110 patients diagnosed with allergic rhinitis with or without concomitant asthma were enrolled in this study. Before beginning sublingual immunotherapy (SLIT), patients were evaluated by analyzing clinical and laboratory parameters. A specific rating was assigned to each parameter to be combined in a total score named PRIS. At baseline (T0) and follow-up [after 12 (T12) and 24 months (T24) of SLIT], a Visual Analogue Scale (VAS) was used to calculate a mean symptom score (MSS). Finally, the percentage variation between the MSS at T0 and at T12 [ΔMSS-12(%)] and T24 [ΔMSS-24 (%)] was measured. We observed a significant improvement of symptoms at T12 and T24 compared to T0 in all groups undergoing SLIT. PRIS was effective in predicting ΔMSS-24 (%) in patients treated with single-allergen SLIT. In addition, PRIS was effective in predicting ΔMSS-24 (%) in both patients with only rhinitis and with concomitant asthma. PRIS assessment can represent a useful tool to individuate potential responders before SLIT prescription.
